The #1 AI-powered therapy

notes – done in seconds

Try for free

The #1 AI-powered therapy notes – done in seconds

Try for free

This blog is brought to you by YUNG Sidekick –

the #1 AI-powered therapy notes – done in seconds

This blog is brought to you by YUNG Sidekick — the #1 AI-powered therapy notes – done in seconds

Try for free – no credit card required

Home

Blog

Therapy

Sleep Disorders in Mental Health: A Clinician's Guide to Transdiagnostic Assessment, Sequencing, and Sleep-Targeted Treatment

Stanley Efrem

Oct 16, 2026

For decades, sleep disturbance occupied a subordinate position in psychiatric formulation. It was listed among the diagnostic criteria for depression, acknowledged as a feature of mania, and otherwise treated as an epiphenomenon—something that would resolve once the “real” disorder was treated. That formulation is now untenable.

A 2025 narrative review in PLOS Mental Health states the revised position without ambiguity: sleep problems, “once considered secondary, are now recognized as active contributors to the onset, course, and relapse of mental illness” . The same review describes insomnia, hypersomnia, and circadian misalignment as “transdiagnostic features, impacting diagnostic presentation, prognostic trajectories, and underlying pathology” . A 2026 APA cover story summarizes the clinical implication: the relationship is bidirectional, sleep troubles often come first, and a meta-analysis of longitudinal studies concluded that insomnia is a significant predictor for the onset of depression, anxiety, alcohol abuse, and psychosis .

This is not an academic revision. It changes what the therapist assesses, what is treated first, how treatment response is measured, and what is documented. A patient who presents with depression and comorbid insomnia is not a patient with one disorder and one symptom. They are a patient with two treatable conditions, and the evidence increasingly suggests that treating the sleep disorder improves the psychiatric disorder—not merely the other way around.

This article examines sleep disorders in mental health as a clinical practice problem: the shared neurobiology that explains the comorbidity, the specific sleep disorders that masquerade as psychiatric conditions, the suicide-risk signal embedded in sleep symptoms, the evidence for sleep-targeted psychotherapy and pharmacotherapy, and the practical sequencing and documentation principles that make treatment defensible.

The Shared Neurobiology: Why Sleep and Psychiatric Disorders Travel Together

The bidirectional model is not a psychological abstraction. It rests on convergent neurobiological mechanisms that the 2025 PLOS review organizes into four domains: circadian system dysregulation, neurotransmitter network dysfunction (GABA, serotonin, dopamine, orexin), affective circuitry involving prefrontal–amygdala interactions, and stress–immune pathways .

The clinical consequence of this shared substrate is that sleep disturbance is not a downstream marker of psychiatric illness. It is a partially independent pathological process that can initiate, amplify, or maintain the psychiatric disorder. The review illustrates this with three specific claims: chronic insomnia increases depression risk, sleep loss can precipitate manic episodes, and distinct sleep architecture anomalies are linked to schizophrenia .

The therapeutic implication is equally specific. Because sleep is “a tractable factor in mental health,” it offers “a potent intervention leverage point” . The review recommends that routine, structured sleep assessment be integrated into psychiatric care, with first-line behavioral and chronobiological strategies such as CBT-I and light/rhythm therapies, and it concludes that directly addressing sleep “significantly improves psychiatric outcomes, reducing symptoms of depression and anxiety, decreasing suicidal ideation, and lowering relapse risk in bipolar disorder and psychoses” .

For the therapist, this is the core rationale for treating sleep as a clinical target rather than a background symptom. The question is no longer whether to address sleep in psychiatric care. It is how to assess it, sequence it, and measure it.

The Sleep Disorders That Masquerade as Psychiatric Conditions

Three sleep disorders are systematically under-recognized in psychiatric practice because their symptoms overlap with psychiatric symptoms, and because psychiatric clinicians are not trained to screen for them.

Obstructive Sleep Apnea

Obstructive sleep apnea is an independent risk factor for cardiovascular disease, and it is highly prevalent among patients with psychiatric disorders . The 2026 evidence on the psychiatric association is substantial. A longitudinal study of more than 30,000 participants in the Canadian Longitudinal Study on Aging found that high risk of OSA was associated with a 40% higher risk of poor mental health outcomes at baseline and at follow-up, and with a 44% increased risk of reporting one or more new mental health conditions over a mean follow-up of 2.9 years . The same analysis found that high OSA risk was associated with an odds ratio of 1.39 for poor mental health at baseline and 1.40 at follow-up .

The diagnostic challenge is precise and clinically consequential. OSA presents with excessive daytime sleepiness, fatigue, and cognitive complaints—symptoms that are indistinguishable from depression, ADHD, and burnout. The 2026 review in L'Encéphale emphasizes that diagnosis poses specific challenges, including difficulty performing sleep recording and the “intricated causes of excessive daytime sleepiness” . It recommends emphasis on reducing daytime sleepiness, nocturnal symptoms, and psychiatric symptoms, and notes that data exist on the efficacy of continuous positive airway pressure in reducing anxiety and depression .

The clinical implication is that every patient with treatment-resistant depression, persistent fatigue, or daytime sleepiness should be screened for OSA, regardless of whether they endorse snoring or witnessed apneas. The STOP questionnaire—snoring, tiredness, observed apnea, and high blood pressure—is a practical screen, with high risk defined as meeting any two of the four items .

Hypersomnolence

Hypersomnolence complaints are common in psychiatric disorders and carry substantial functional burden, yet they remain “under-recognized and frequently under-investigated” . The 2026 narrative review in L'Encéphale distinguishes three partially overlapping dimensions: excessive daytime sleepiness, excessive total sleep time or need for sleep, and sleep or wake inertia .

The prevalence data are striking: hypersomnolence affects 40–50% of patients in major depressive episodes and is frequently linked to circadian factors, comorbid insomnia, OSA, and medication effects . Objective long sleep time is common among depressed patients with hypersomnolence, and similar observations are made for ADHD, anxiety and trauma-related disorders, and psychotic disorders .

The review proposes a three-step care algorithm that is directly usable in psychiatric practice: first, universal behavioral and circadian measures; second, targeted treatment of the underlying cause—antidepressant optimization, chronotherapeutics, CBT-I, CPAP or mandibular advancement devices for OSA, specific management for restless legs or parasomnias, and specialist evaluation for narcolepsy or idiopathic hypersomnia; third, management of residual symptoms, including light therapy and carefully selected wake-promoting agents when indicated .

The clinical discipline here is etiological. Hypersomnolence in a depressed patient is not automatically a symptom of depression. It may be OSA, it may be a medication effect, it may be idiopathic hypersomnia, or it may be a circadian misalignment. The three-step algorithm prevents the reflex of increasing the antidepressant dose when the problem is sleep-disordered breathing.

Idiopathic Hypersomnia and Narcolepsy

The central disorders of hypersomnolence carry a high psychiatric burden. A nationwide multicenter study in South Korea found that 52.9% of patients with central disorders of hypersomnolence had depression burden, and 38.7% had clinical insomnia . The risk was most pronounced in idiopathic hypersomnia, where the prevalence of depression burden reached 63.9%, compared with 36.7% in narcolepsy type 2 . Clinical insomnia and young adult age were independent risk factors for depression burden .

The clinical implication is that idiopathic hypersomnia and narcolepsy should be on the differential for patients with persistent hypersomnolence and depression, particularly when the sleepiness is not explained by insufficient sleep, OSA, or medication. The authors call for regular psychiatric screening and integrated multidisciplinary care .

The Suicide-Risk Signal: Insomnia and Nightmares as Proximal, Modifiable Risk Factors

The most clinically urgent finding in the sleep–mental health literature is that sleep disturbance is not merely associated with suicidality—it is a proximal, modifiable risk factor that operates independently of psychiatric diagnosis.

A 2026 review in L'Encéphale concludes that insomnia, nightmares, abnormal sleep duration, and circadian rhythm disruptions are “consistently associated with suicidal ideation, suicide attempts, and suicide deaths, independently of psychiatric disorders” . The same review reports that any form of sleep alteration is associated with a relative risk of suicidal behaviors ranging from 1.94 to 2.79 . Objective sleep measures—nocturnal wakefulness and REM sleep alterations—further support the association, and the proposed mechanisms include inflammation, neurotransmitter dysregulation, impaired prefrontal–limbic connectivity, hopelessness, and nocturnal isolation .

The developmental data sharpen the clinical priority. A 2026 study of 744 depressed adolescents and young adults (mean age 18.31, 76.6% female) found that insomnia and hypersomnia had stronger direct associations with suicide risk than the depression-mediated pathway . The association was strongest in the youngest patients: the insomnia–suicide association was β = 1.950 in those aged 15 or younger, β = 1.662 at ages 16–18, and β = 1.287 at ages 19–25 . The authors conclude that sleep symptoms “directly elevate suicide risk, exerting a stronger influence than depressive symptoms,” and call for early, sleep-focused interventions in youth suicide prevention .

The clinical implications are specific and actionable. Suicide risk assessment should incorporate sleep-related interview questions, validated questionnaires, and objective measures such as actigraphy where feasible . The assessment should distinguish insomnia from nightmares from hypersomnia, because each carries independent risk and each has a different treatment. And the treatment of sleep disturbance should be understood as a suicide-prevention intervention, not merely a comfort measure. Interventions targeting sleep—CBT-I, sleep medications, and Imagery Rehearsal Therapy—show promise in reducing suicidal ideation .

Sleep-Targeted Psychotherapy: What Works, for Whom, and in What Dose

CBT-I: The First-Line Psychological Treatment

Cognitive behavioral therapy for insomnia is the first-line psychological treatment for chronic insomnia, and the 2025 PLOS review identifies it, alongside light and rhythm therapies, as a first-line behavioral and chronobiological strategy in psychiatric care .

The evidence in depression is substantial. A 2026 randomized controlled trial of digital CBT-I added to care-as-usual for depression (N = 140, 120 women, mean age 39.76) found large treatment effects at 12 and 24 weeks, with a significant reduction in depressive symptom severity (3.34 and 2.83 points; ps < .001; ds = 0.66–0.78) . Treatment effects in favor of digital CBT-I were also found for most secondary outcomes (ds = 0.33–1.94), including insomnia severity, daytime sleepiness, fatigue, and well-being . The authors conclude that the efficacy of digital CBT-I “is not limited to insomnia populations alone, but can also achieve broader effects on measures of depression” .

The individual-participant meta-analysis of digital behavioral therapy for insomnia (dBT-I) with sleep restriction therapy as the central component (dBT-I n = 220; control n = 270) found significant reductions in anxiety at week 8 (mean difference −0.94 GAD-7 points, 95% CI −1.80 to −0.09, p = .030) and at week 16 (−0.94, 95% CI −1.86 to −0.02, p = .044), and in depression at week 8 (−0.40 SDs, 95% CI −0.66 to −0.14, p = .003) and week 16 (−0.44 SDs, 95% CI −0.72 to −0.17, p = .002), with no evidence that effects diminished between timepoints . The authors are candid about the magnitude: the reductions were less than the smallest detectable difference for these questionnaires, and they describe dBT-I as “a scalable intervention with modest mental health benefits extending beyond insomnia” .

The clinical synthesis is that CBT-I is effective for insomnia and produces modest but real transdiagnostic improvements in depression and anxiety. It is not a substitute for depression treatment, but it is a legitimate adjunct that addresses a modifiable mechanism. The digital format is scalable, but the effect sizes are smaller than in-person trials, and retention is a known challenge.

CBT-I in Bipolar Disorder: Sequencing and Adaptation

CBT-I adapted for bipolar disorder (CBTI-BD) has the most consistent evidence among sleep-focused interventions in bipolar disorder. A 2026 systematic review of eleven studies found that CBTI-BD “consistently improved sleep efficiency, latency, and total sleep time and were associated with reductions in depressive symptoms” . The review also reports that bright light therapy yielded mixed results, the Benson Relaxation Technique showed improvements in sleep quality and emotional regulation, and among pharmacological approaches, melatonin improved circadian alignment and sleep parameters without mood destabilization, while suvorexant showed limited efficacy and antidepressants were linked to poorer sleep quality and greater impulsivity during euthymia .

The review is explicit about the evidence limits: each intervention was evaluated in a single clinical phase, and the available evidence cannot determine whether clinical phase or chronotype moderates treatment response . It recommends routine screening for insomnia and circadian misalignment in bipolar disorder .

The clinical discipline in bipolar disorder is that sleep-focused intervention must be phase-aware. CBTI-BD has been tested primarily in euthymic and interepisode samples . Starting sleep restriction during a hypomanic or mixed episode is a clinical risk, and the therapist should coordinate with the prescriber before initiating sleep restriction in a patient with a history of mania.

Nightmares and PTSD: CBT-I Plus Imagery Rehearsal Therapy

Insomnia and nightmares are reported in 70–90% and 70% of PTSD cases respectively, making them the most prevalent sleep disturbances associated with the condition . They are associated with more severe PTSD, depression, and anxiety symptoms, functional impairment, lower quality of life, and increased suicidality .

The strongest real-world evidence for a combined protocol comes from a 2026 study of 60 outpatients (78% male, mean age 50.7) at an operational stress injury clinic who attended 10 weekly 2-hour sessions of combined CBT-I and Imagery Rehearsal Therapy . From baseline to post-intervention, there were significant reductions in insomnia severity, nightmare distress and frequency, PTSD severity, dysfunctional beliefs about sleep, and insomnia-related ruminations, while life satisfaction increased . Sleep-diary indices improved: shorter sleep onset latency (t(37) = 5.0, p ≤ .001), longer total sleep time (t(37) = −1.7, p = .049), less wake after sleep onset (t(37) = 1.8, p = .037), and higher sleep efficiency (t(37) = −5.1, p ≤ .001) . Improvements in insomnia severity (r(48) = .35, p = .013) and nightmare distress (r(46) = .36, p = .012) both correlated with improvements in PTSD .

The authors highlight a clinically important nuance: “successfully treating one of two sleep disorders limits PTSD symptoms improvements,” and the findings support “transdiagnostic sleep disturbance as a treatment target for PTSD” . In other words, treating insomnia without addressing nightmares—or nightmares without addressing insomnia—produces incomplete benefit. The combined protocol addresses both.

Pharmacological Options: What the 2026 Algorithm and Trials Show

The 2026 Harvard South Shore psychopharmacology algorithm for secondary insomnia provides condition-specific recommendations that are directly usable in collaborative care . For insomnia secondary to major depressive disorder, it suggests eszopiclone and trazodone; for generalized anxiety disorder, eszopiclone and zolpidem; for PTSD, prazosin; and for a bipolar manic episode, a second-generation antipsychotic . The algorithm emphasizes a detailed biopsychosocial evaluation first, management of medical causes, and nonpharmacological treatment for conditioned insomnia that persists after other causes resolve .

For PTSD-related nightmares, the evidence base expanded significantly in 2026. A multicenter, double-blind, randomized, placebo-controlled trial of dronabinol (2.5–15 mg) once daily before bedtime for 10 weeks in 171 adults with PTSD and recurrent nightmares (mean age 37.9, 79.3% female) found a significantly greater reduction in CAPS-IV B2 nightmare frequency and intensity scores with dronabinol than placebo (between-group difference −1.50; 95% CI −2.28 to −0.71; Cohen's d = 0.65; P < 0.001) . Adverse events occurred in 89.7% of the dronabinol group and 77.1% of the placebo group, with treatment discontinuation due to adverse events in 5.7% and 7.2% respectively, and serious adverse events in 8.0% versus none . The authors conclude that dronabinol reduces nightmare frequency and intensity, though long-term efficacy and safety require further evaluation .

The clinical caution is essential: dronabinol is not a first-line treatment, it carries a substantial adverse-event burden, and it should be considered only in collaboration with a prescriber, after first-line approaches such as prazosin and Imagery Rehearsal Therapy have been considered.

Assessment and Documentation: The Practical Framework

The 2025 PLOS review recommends “routine, structured sleep assessment” integrated into psychiatric care . For the therapist, this means moving beyond the single question “How are you sleeping?” to a structured assessment that captures the specific sleep disorder, its severity, and its functional impact.

The assessment should include a sleep diary (at least one to two weeks) to capture sleep–wake patterns, sleep onset latency, wake after sleep onset, total sleep time, and variability. Actigraphy is increasingly used in research and specialty practice, and the bipolar literature demonstrates that actigraphy-derived metrics—sleep variability and the Sleep Regularity Index—predict depressive symptom severity and functional impairment in bipolar disorder . The Insomnia Severity Index provides a validated severity measure, and the STOP questionnaire screens for OSA risk . For nightmares, frequency and distress should be assessed separately, because they respond differently to treatment .

The documentation should capture the specific sleep disorder or symptom cluster (insomnia, nightmare disorder, hypersomnolence, suspected OSA, circadian misalignment), the assessment instrument and result, the functional impact (daytime sleepiness, cognitive complaints, occupational impairment), the suicide-risk assessment with attention to sleep symptoms, the treatment modality and sequencing rationale, and the response trajectory. For patients on sleep-related pharmacotherapy, the documentation should note the prescriber, the agent, the dose, and the monitoring plan.

The clinical logic of sequencing deserves explicit documentation. The default sequence in most cases is: behavioral and circadian measures first; targeted treatment of the underlying cause second; residual symptom management third . When the patient has both a psychiatric disorder and a sleep disorder, the most disabling condition should have priority for treatment . When the patient has both insomnia and nightmares, both should be treated, because treating one limits improvement in the other .

Practical Principles for Clinicians

Screen for sleep disorders in every psychiatric evaluation. Insomnia, OSA, hypersomnolence, and circadian misalignment are transdiagnostic and consequential. The single question is insufficient.

Screen for OSA in treatment-resistant depression, persistent fatigue, and daytime sleepiness. High OSA risk is associated with a 40% higher risk of poor mental health outcomes and a 44% increased risk of new mental health conditions . Use the STOP questionnaire as a practical screen.

Treat sleep as a suicide-prevention target. Insomnia and nightmares are independently associated with suicidal ideation, attempts, and deaths, with relative risks of 1.94 to 2.79 for any sleep alteration . In adolescents, sleep symptoms have stronger direct associations with suicide risk than depressive symptoms . Assess at every session and document.

Use CBT-I as the first-line psychological treatment for insomnia, and expect modest transdiagnostic benefit. Digital CBT-I added to depression care produced large effects on depressive symptoms (ds = 0.66–0.78) , while the individual-participant meta-analysis found modest but significant reductions in anxiety and depression . Position CBT-I accurately: effective for insomnia, adjunctive for psychiatric symptoms.

Adapt CBT-I to bipolar disorder and respect the phase. CBTI-BD improves sleep and depressive symptoms in euthymic and interepisode samples . Melatonin improves circadian alignment without mood destabilization, while antidepressants are linked to poorer sleep quality and greater impulsivity during euthymia . Coordinate with the prescriber before sleep restriction in a patient with a history of mania.

Combine CBT-I and Imagery Rehearsal Therapy for PTSD. The combined 10-session protocol improved insomnia, nightmare distress and frequency, PTSD severity, and sleep-diary indices, with improvements in insomnia and nightmare distress correlating with PTSD improvement . Treating only one of the two sleep disorders limits PTSD symptom improvement .

Know the condition-specific pharmacological options, and collaborate. The 2026 algorithm suggests eszopiclone and trazodone for insomnia in major depression, eszopiclone and zolpidem in generalized anxiety disorder, prazosin in PTSD, and a second-generation antipsychotic in bipolar mania . Dronabinol reduced PTSD nightmare frequency and intensity in a 2026 RCT but carries a substantial adverse-event burden .

Assess hypersomnolence etiologically, not reflexively. Hypersomnolence affects 40–50% of patients in major depressive episodes and may be driven by circadian factors, comorbid insomnia, OSA, or medication effects . Follow the three-step algorithm: universal behavioral and circadian measures, targeted treatment of the underlying cause, then residual symptom management .

Document the specific disorder, the instrument, the sequencing rationale, and the suicide-risk assessment. The documentation should make clear that sleep was assessed as a clinical domain, not as a residual symptom.

FAQ

Is insomnia a symptom of depression or a separate disorder?

It is both, and the distinction matters clinically. Insomnia is a diagnostic criterion for depression, but it is also an independent disorder that predicts the onset of depression, anxiety, alcohol abuse, and psychosis . The 2025 PLOS review describes sleep problems as “active contributors to the onset, course, and relapse of mental illness,” not merely secondary symptoms . Treating insomnia as a separate target improves psychiatric outcomes.

What is the first-line treatment for insomnia in a patient with a psychiatric disorder?

CBT-I is the first-line psychological treatment, and the 2025 PLOS review identifies it, alongside light and rhythm therapies, as a first-line behavioral and chronobiological strategy in psychiatric care . Digital CBT-I added to depression care produced large effects on depressive symptoms (ds = 0.66–0.78) . Pharmacotherapy is condition-specific and should be selected in collaboration with a prescriber.

How common is obstructive sleep apnea in psychiatric patients, and why does it matter?

OSA is highly prevalent among patients with psychiatric disorders, and the association is bidirectional . High OSA risk is associated with a 40% higher risk of poor mental health outcomes and a 44% increased risk of new mental health conditions over follow-up . CPAP has data showing reductions in anxiety and depression . Screening is essential because OSA presents with fatigue, sleepiness, and cognitive complaints that mimic depression and ADHD.

How should I assess suicide risk in a patient with insomnia or nightmares?

Incorporate sleep-related interview questions, validated questionnaires, and objective measures such as actigraphy where feasible . Insomnia, nightmares, abnormal sleep duration, and circadian disruption are associated with suicidal ideation, attempts, and deaths independently of psychiatric diagnosis, with relative risks of 1.94 to 2.79 . In adolescents, sleep symptoms have stronger direct associations with suicide risk than depressive symptoms, particularly in those aged 15 or younger .

What is the evidence for combining CBT-I and Imagery Rehearsal Therapy in PTSD?

A 2026 study of 60 outpatients at an operational stress injury clinic delivered 10 weekly 2-hour sessions of combined CBT-I and Imagery Rehearsal Therapy. The intervention produced significant reductions in insomnia severity, nightmare distress and frequency, PTSD severity, dysfunctional sleep beliefs, and insomnia-related ruminations, with improved sleep-diary indices . Improvements in insomnia severity and nightmare distress both correlated with PTSD improvement, and the authors emphasize that treating only one of the two sleep disorders limits PTSD symptom improvement .

What does the 2026 psychopharmacology algorithm recommend for secondary insomnia?

The Harvard South Shore algorithm recommends eszopiclone and trazodone for insomnia secondary to major depressive disorder, eszopiclone and zolpidem for generalized anxiety disorder, prazosin for PTSD, and a second-generation antipsychotic for a bipolar manic episode . It emphasizes a detailed biopsychosocial evaluation, management of medical causes, and nonpharmacological treatment for conditioned insomnia that persists after other causes resolve .

Is dronabinol an option for PTSD-related nightmares?

A 2026 multicenter RCT of dronabinol (2.5–15 mg nightly for 10 weeks) in 171 adults found a significantly greater reduction in nightmare frequency and intensity than placebo (between-group difference −1.50; Cohen's d = 0.65; P < 0.001) . However, adverse events occurred in 89.7% of the dronabinol group, serious adverse events in 8.0%, and the authors state that long-term efficacy and safety require further evaluation . It is not a first-line option and should be considered only in collaboration with a prescriber.

How should hypersomnolence be assessed in a depressed patient?

Distinguish three dimensions: excessive daytime sleepiness, excessive total sleep time or need for sleep, and sleep or wake inertia . Hypersomnolence affects 40–50% of patients in major depressive episodes and may be driven by circadian factors, comorbid insomnia, OSA, or medication effects . Follow the three-step algorithm: universal behavioral and circadian measures, targeted treatment of the underlying cause (including antidepressant optimization, chronotherapeutics, CBT-I, CPAP, and specialist evaluation for narcolepsy or idiopathic hypersomnia), then residual symptom management .